Novogenia AG (ticker: 7V0, formerly Darwin AG), an international healthcare company specializing in human genetics and personalized health products, has published its issuer report for the first half of 2026. The report reveals a 7% decline in consolidated revenue to EUR 25.7 million, down from EUR 26.5 million in the prior-year period. The decline was primarily due to lower volumes in the pharmaceutical and medical device trading segment, which was impacted by regulatory changes. However, the company's core DNA analysis and personalized products segment posted positive revenue growth compared to the same period last year.
CEO Dr. Daniel Wallerstorfer commented, "The financial performance in the first half of 2026 did not meet our expectations in all business areas. Thus, we have not yet been able to realize our ambitious growth plans. However, we are encouraged by the positive year-on-year development of our core business in DNA analyses and personalized health products, as well as by a significant reduction in our cost base." The company achieved cost savings in materials, personnel, and other operating expenses, leading to an improvement in operating profit of approximately EUR 2.7 million. Despite this, EBIT remained negative at EUR -4.7 million, an improvement of 4.1% year-over-year, but the prior-year period benefited from one-time effects that boosted other operating income.
Consolidated net income for H1 2026 was EUR -2.1 million, compared to a positive EUR 2.0 million in the previous year, which had been bolstered by a significantly higher financial result. As of June 30, 2026, Novogenia Group held cash and cash equivalents of EUR 39.8 million, down from EUR 71.9 million, but the company remains in a solid financial position to drive further development.
Strategically, Novogenia made significant progress in the first half. The collaboration with 10X Health Systems was expanded through a joint product pipeline, and the enhanced Methylation Test MGT Plus was successfully launched in the U.S. market. In collaboration with G42 in Abu Dhabi, preparations for a Middle East market launch were advanced, including adapting products to local requirements and preparing for Halal certification. The company also launched the Multi-Cancer Check and established a new software platform for its NovoDaily product line. Construction of a new company site in Hallwang near Salzburg commenced, with completion planned for early 2028. The facility will cover more than 9,300 square meters and provide modern laboratory and production capacities. Additionally, the renaming from Darwin AG to Novogenia AG was implemented in July 2026, consolidating brand identity.
Novogenia will engage with investors at several upcoming conferences, including the 5th Zurich Investor Day on September 29, 2026, and the Abu Dhabi Future Health Summit from October 20-22, 2026, where CEO Dr. Wallerstorfer will present personalized health solutions for the first time in the Middle East. The company aims to mitigate the impact of changes to digital platform algorithms on its sales channels while further reducing its cost base. Through these measures, Novogenia seeks to accelerate the positive development of its core business and strengthen its position in the growing market for personalized prevention and healthcare.
For more information, visit https://novogenia.com/novogenia-ag. The original release is available on www.newmediawire.com.
